Biotech Values

[DewDiligence]

IDRA's HCV program:

…is this trial even a true success if the drug only achiived 1 log10 reduction in a portion of the patients when up-front they define these null responders as having been unable to achieve a 2 log10 reduction from SoC?

I concur with your rhetorical question—IDRA hasn’t shown anything of consequence in this program yet.

From a big picture standpoint, I'm not sure it's really even worth wasting time discussing the significance of this drug (designed to replace interferon) inasmuch as we are presumably moving towards an all-oral HCV treatment regimen. I'm trying to save you some time Dew : )

The IMO-2125 program is marginal, IMO; I have it logged in paragraph #6 of the “HCV: Most Likely to Succeed” post in #msg-44700654, FWIW. Thanks for the update.